Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 8, 2009
Grant Date -
Nov 8, 2007
app pub date -
Jul 10, 2002
filing date -
Jul 10, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and aniino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully